Regenxbio (NASDAQ: RGNX) reported Q1 EPS of $3.04, $2.04 better than the analyst estimate of $1.00. Revenue for the quarter came in at $132.39 million versus the consensus estimate of $61.05 million.

Financial Guidance

REGENXBIO reiterates that it expects full-year 2018 cash burn to be between $85 million and $95 million, which will support the continued development of its lead product candidate programs. Full-year 2018 cash burn guidance excludes the effect of the upfront payment of $80 million and any other potential consideration that may be received from AveXis in connection with the previously announced amendment to our license agreement in January 2018 for the development and commercialization of treatments for SMA. Subject to this exclusion, full-year 2018 cash burn will be measured as the decrease in cash, cash equivalents and marketable securities from December 31, 2017 to December 31, 2018.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.